PLERIXAFOR

( DrugBank: Plerixafor / KEGG DRUG: Plerixafor )


5 diseases
IDDisease name (Link within this page)Number of trials
20Adrenoleukodystrophy1
51Scleroderma1
65Primary immunodeficiency9
IDDisease name (Link within this page)Number of trials
285Fanconi anemia5
299Cystic fibrosis1

20. Adrenoleukodystrophy


Clinical trials : 71 / Drugs : 100 - (DrugBank : 29) / Drug target genes : 22 - Drug target pathways : 125 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

51. Scleroderma


Clinical trials : 740 / Drugs : 813 - (DrugBank : 165) / Drug target genes : 140 - Drug target pathways : 231 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

65. Primary immunodeficiency


Clinical trials : 866 / Drugs : 858 - (DrugBank : 122) / Drug target genes : 108 - Drug target pathways : 232 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

285. Fanconi anemia


Clinical trials : 72 / Drugs : 131 - (DrugBank : 32) / Drug target genes : 34 - Drug target pathways : 172 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

299. Cystic fibrosis


Clinical trials : 1,885 / Drugs : 1,782 - (DrugBank : 252) / Drug target genes : 110 - Drug target pathways : 190 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries